In vitro hepatic metabolism of CYP3A-mediated drugs quinine and midazolam in the common brush-tailed possum (Trichosurus vulpecula)

Environmental Toxicology and Chemistry

Volumn 17, Issue 2, 1998, Pages 317-324

  Ho, Ping Chuen ^a   Luo, Xiao Xing ^a   Macauley, Jackie S ^a   Grigor, Murray R ^a   Wanwimolruk, Sompon ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cytochromes 3A; Drug metabolism; Midazolam; Possum liver; Quinine

Indexed keywords

CYTOCHROME P450; MIDAZOLAM; QUININE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; ECOTOXICITY; ENVIRONMENTAL IMPACT ASSESSMENT; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; MAMMAL; NONHUMAN; PRIORITY JOURNAL;

ALOPIAS; ANIMALIA; CINCHONA PUBESCENS; MAMMALIA; STAPHYLOCOCCUS PHAGE 3A; TRICHOSURUS VULPECULA; TRIXIS;

EID: 0031908752     PISSN: 07307268     EISSN: None     Source Type: Journal    
DOI: 10.1897/1551-5028(1998)017<0317:IVHMOC>2.3.CO;2     Document Type: Conference Paper

References (42)

1. Livingstone PG. 1994. The use of 1080 in New Zealand. Proceedings, Science Workshop on 1080, Christchurch, New Zealand, December 12-14, 1993. R Soc N Z Misc Ser 28:1-9.
2. Eason CT, Frampton CM, Henderson R, Thomas MD, Morgan DR. 1993. Sodium mono-fluoroacetate and alternative toxins for possum control. N Z J Zool 20:329-334.
3. Halpert JR, Guengerich FP, Bend JR, Correia MA. 1994. Contemporary issues in toxicology. Selective inhibitions of cytochromes P450. Toxicol Appl Pharmacol 125:163-175.
4. Wrighton SA, Stevens JC. 1992. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
5. Gonzalez FJ. 1992. Human cytochromes P450: Problems and prospects. Trends Pharmacol Sci 13:345-352.
6. Watkins PB. 1994. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184.
7. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. 1996. Inhibition and kinetic of cytochrome CYP3A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
8. Zhang XJ, Thomas PE. 1996. Erythromycin as a specific substrate for cytochrome P4503A isozymes and identification of a high-affinity erythromycin N-demethylase in adult female rates. Drug Metab Dispos 24:23-27.
9. Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y. 1993. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 21:978-985.
10. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK. 1995. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 23:631-636.
11. Zhao XJ, Yokoyama H, Chiba K, Wanwimolruk S, Ishizaki T. 1996. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther 279:1327-1334
12. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. 1989. Oxidation of midazolam triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
13. 3C in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. Biochem Pharmacol 37:1947-1953.
14. Li G, U Klotz. 1990. Inhibitory effect of omeprazole on the metabolism of midazolam in vitro. Arzneim Forsch 40:1105-1107.
15. Sharer JE, LA Shipley, Vandenbranden MR, Binkley SN, Wrighton SA. 1995. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 23:1231-1241.
16. Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S. 1997. Evidence for an involvement of human CYP3A in the hepatic metabolism of quinine. Br J Clin Pharmacol 43: 245-252.
17. Zhang H, Wanwimolruk S, Coville PF. 1995. In vitro hepatic metabolism of quinine in rats. Proceedings, 29th Annual Meeting, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, University of Adelaide, Adelaide, Australia, December 3-6, p 25.
18. Zhang H, Coville PF, Wanwimolruk S. 1996. Sex and strain differences in hepatic quinine 3-hydroxylase activity in the rat. Proceedings, 30th Annual Meeting, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, University of Monash, Clayton, Australia, December 8-13, p 35.
19. Beedham C, Al-Tayib Y, Smith JA. 1992. Role of guinea pig and rabbit hepatic aldehyde oxidase in oxidative in vitro metabolism of cinchona antimalarials. Drug Metab Dispos 20:889-895.
20. Wanwimolruk S, Wong WS, Ho PC. 1996. In vitro hepatic me- tabolism of quinine in cow, pig, and sheep. Pharm Sci 2:295-298.
21. Butler MA, et al. 1992. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127.
22. McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, Tukey RH. 1990. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res 50: 3367-3376.
23. Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275.
25. Birkett DJ, Mackenzie PI, Veronese ME, Miners JO. 1993. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 14:292-294.
26. Tassaneeyakul W, et al. 1992. Caffeine as a probe for human cytochromes P450: Validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2:173-183.
27. Veronese ME, et al. 1993. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 289:533-538.
28. Veronese ME, Miners JO, Rees DLP, Birkett DJ. 1993. Tolbutamide hydroxylation in humans: Lack of bimodality in 106 healthy subjects. Pharmacogenetics 3:86-93.
29. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, ME Veronese. 1994. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 37:413-420.
30. Dayer P, Kronbach T, Eichelbaum M, Meyer UA. 1987. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation: Characterization of bufuralol 1'-hydroxylation in liver microsome of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol 36:4145-4152.
31. Pichard L, Fabre I, Domergue J, Saint-Aubert B, Mourad G, Maurel P. 1990. Cyclosporin A drug interaction. Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
32. Kharasch ED, Thummel KE. 1993. Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? Anesth Analg 76:1033-1039.
33. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED. 1995. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 23:490-496.
34. Wanwimolruk S, Wong SM, Zhang H, Coville PF. 1995. Simultaneous determination of quinine and a major metabolite 3-hydroxyquinine in biological fluids by HPLC without extraction. J Liq Chromatogr 19:293-305.
35. Wrighton SA, Ring BJ. 1994. Inhibition of human CYP3A catalysed l'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmacol Res 11:921-924.
36. Murry M, Reidy GF. 1990. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 42:85-101.
37. Tassaneeyakul W, Birkett DJ, McManus ME, Veronese ME, Andersson T, Tukey RH, Miners JO. 1994. Caffeine metabolism by human hepatic cytochromes P450: Contribution of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 47:1767-1776.
38. Saggers VH, Hariratnajothi N, McLean AEM. 1970. The effect of diet and phenobarbitone on quinine metabolism in the rat and in man. Biochem Pharmacol 19:499-503.
39. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E. 1994. Midazolam is metabolised by at least three different cytochrome P450 enzymes. Br J Anaeth 73:658-661.
40. Forrester LM, et al. 1992. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281:359-368.
41. Gerlach JC, Encke J, Hole O, Muller C, Ryan CJ, Neuhaus P. 1994. Bioreactor for a larger scale hepatocyte in vitro perfusion. Transplantation 58:984-988.
42. Schläppi B. 1983. Safety aspects of midazolam. Br J Clin Pharmacol 16:37S-41S.